Reference and Research Laboratory for Parasitology, National Centre for Microbiology, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC-ISCIII), Madrid, Spain.
Microbiol Spectr. 2023 Jun 15;11(3):e0335422. doi: 10.1128/spectrum.03354-22. Epub 2023 Apr 4.
Leishmaniasis is an endemic parasitic disease in at least 98 countries. In Spain, it is considered a zoonosis caused by Leishmania infantum, with an annual incidence of 0.62 cases/100,000 inhabitants. The predominant clinical manifestations are the cutaneous (CL) and visceral forms (VL), and the diagnosis is performed by parasitological, serological, and molecular tests. At the WHO Collaborating Center for Leishmaniasis (WHOCCLeish), routine diagnostic tests are based on a nested PCR (Ln-PCR), culture, and serological tests. To simplify our PCR protocol, we aimed to develop and validate a ready-to-use nested gel-form PCR (LeishGelPCR) and a duplex real-time PCR (qPCR) that allowed simultaneous detection of and mammalian DNA as an internal control (Leish-qPCR). Clinical validation was performed in 200 samples from the WHOCCLeish collection; 92 and 85 out of 94 and 87 samples were positive by LeishGelPCR and Leish-qPCR, respectively, showing a sensitivity of 98% in both approaches. The specificity was 100% for LeishGelPCR and 98% for Leish-qPCR. The limits of detection of both protocols were similar (0.5 and 0.2 parasites/reaction). Parasite loads in VL and CL forms were similar, although high loads were observed when invasive samples were tested. In conclusion, LeishGelPCR and Leish-qPCR showed excellent performance in the diagnosis of leishmaniasis. These new forms of 18S rRNA gene PCR are equivalent to Ln-PCR and can be introduced in the algorithm for CL and VL diagnosis. Although the gold standard for diagnosis of leishmaniasis is the microscopic observation of amastigotes, molecular techniques are becoming a cost-efficient alternative. Currently, PCR is a routine resource that is used in many reference microbiology laboratories. In this article, we have described two ways to improve the reproducibility and usability of the molecular detection of spp. These new approaches could be introduced even in middle- and low-resource laboratories; one is a ready-to-use gel-form system of a nested PCR and the other is a real-time PCR. We show why molecular diagnosis is the best methodology to confirm a clinical suspicion of leishmaniasis with higher sensitivity than traditional methods, thus facilitating early diagnosis and timely treatment of human leishmaniasis.
利什曼病是一种至少在 98 个国家流行的寄生虫病。在西班牙,它被认为是一种由利什曼原虫引起的动物源性疾病,年发病率为每 10 万人中有 0.62 例。主要的临床表现为皮肤利什曼病(CL)和内脏利什曼病(VL),诊断方法包括寄生虫学、血清学和分子检测。在世界卫生组织利什曼病合作中心(WHOCCLeish),常规诊断检测基于巢式 PCR(Ln-PCR)、培养和血清学检测。为了简化我们的 PCR 方案,我们旨在开发和验证一种即用型巢式凝胶形式 PCR(LeishGelPCR)和一种双靶 real-time PCR(qPCR),允许同时检测 和哺乳动物 DNA 作为内部对照(Leish-qPCR)。临床验证在 WHOCCLeish 收集的 200 个样本中进行;LeishGelPCR 和 Leish-qPCR 分别检测到 94 个和 87 个样本中的 92 个和 85 个样本呈阳性,两种方法的灵敏度均为 98%。LeishGelPCR 和 Leish-qPCR 的特异性均为 100%。两种方案的检测限相似(0.5 和 0.2 个寄生虫/反应)。VL 和 CL 形式的寄生虫负荷相似,尽管当测试侵袭性样本时观察到高负荷。总之,LeishGelPCR 和 Leish-qPCR 在利什曼病的诊断中表现出优异的性能。这些新形式的 18S rRNA 基因 PCR 与 Ln-PCR 相当,可引入 CL 和 VL 诊断算法中。虽然利什曼病诊断的金标准是观察无鞭毛体,但分子技术正在成为一种具有成本效益的替代方法。目前,PCR 是许多参考微生物学实验室使用的常规资源。在本文中,我们描述了两种提高 spp. 分子检测重现性和可用性的方法。这些新方法甚至可以在中低资源实验室中引入;一种是即用型巢式 PCR 凝胶形式系统,另一种是 real-time PCR。我们展示了为什么分子诊断是一种比传统方法具有更高灵敏度的确认利什曼病临床怀疑的最佳方法,从而有助于早期诊断和及时治疗人类利什曼病。